


## PSMA binder-1

Cat. No.:	HY-158123
CAS No.:	2170653-14-0
Molecular Formula:	C <sub>21</sub> H <sub>26</sub> N <sub>4</sub> O <sub>8</sub>
Molecular Weight:	462.45
Target:	PSMA
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with <sup>111</sup>In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with <sup>225</sup>Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT), has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC)<sup>[1][2]</sup>.

### REFERENCES

- [1]. Sun M, et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. *Curr Oncol Rep*. 2021 Mar 29;23(5):59.
- [2]. Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. *Cancer Research*, 2024, 84(6\_Supplement): 6033-6033.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA